Antibody-drug conjugates (ADCs) have reshaped oncology by delivering potent chemotherapy directly to cells that carry a chosen surface protein. HER2 and TROP2 built the category. Late-line colorectal cancer, however, has stayed difficult for targeted payloads.
On October 7, 2026, AbbVie announced that the FDA granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A; ABBV-400), an investigational c-Met-directed ADC carrying a topoisomerase 1 inhibitor (Top1i) payload. One designation covers Temab-A plus bevacizumab in refractory metastatic colorectal cancer (mCRC). The other covers Temab-A monotherapy in previously treated, EGFR wild-type, c-Met protein-expressing, non-squamous non-small cell lung cancer (NSCLC). These are the first Breakthrough Therapy Designations for the program, and AbbVie says its ADC portfolio now holds four.
In This Deep Dive:
- Why this matters now: limited options after second-line colorectal cancer.
- What actually happened: two designations, both based on the first-in-human M21-404 study.
- The obvious read versus the deeper signal: a lung extension versus a new colorectal opportunity.
- ADC architecture and competitive taxonomy across c-Met, HER2 and TROP2.
- The Evidence Ladder, clinical economics and the HealthTech Investor's Signal.
- Counter-thesis and four indicators to watch over the next 12 to 24 months.
Why this matters now
Colorectal cancer is among the most common causes of cancer death worldwide. Modern first- and second-line regimens built on fluoropyrimidines, oxaliplatin, irinotecan and biologics have extended survival, but patients whose disease progresses after those therapies have few effective options. Standard later-line treatments such as trifluridine/tipiracil (with or without bevacizumab), regorafenib and fruquintinib offer modest benefit.
A targeted ADC that produces responses in this setting would be meaningful for patients and for cancer centers looking for options beyond salvage chemotherapy.
What actually happened
Both designations were based primarily on the first-in-human Phase 1 study M21-404 (NCT05029882). In data presented at ESMO 2025, Temab-A 2.4 mg/kg plus bevacizumab produced a median progression-free survival of 6.8 months in biomarker-unselected patients with third-line or later colorectal cancer, compared with 4.2 months for a trifluridine/tipiracil plus bevacizumab reference arm, as reported by OncLive. Coverage of the colorectal monotherapy cohort reported an overall response rate of 15.6% and a disease control rate of 74.6% in heavily pretreated patients.
Breakthrough designation speeds up FDA interaction and review; it is not an approval, and the cohorts involved are early and relatively small.
The obvious read versus the deeper signal
The obvious read treats this as a lung cancer line extension for AbbVie's c-Met franchise, which already includes telisotuzumab vedotin (Emrelis), granted accelerated approval in 2025 for previously treated c-Met protein-high NSCLC.
The deeper signal is colorectal cancer. c-Met is broadly expressed in gastrointestinal tumors, and a Top1i payload with bystander activity may help address the uneven antigen expression that has limited earlier ADCs. If confirmatory trials hold up, AbbVie would have a targeted option in a large late-line setting where ADCs have not yet established themselves.
